#1 Clinical Trials Search in Europe

Azacitidine

Azacitidine, also known as 5-azacytidine or Vidaza, is a drug being studied in various clinical trials for its potential in treating different types of cancer and blood disorders. These trials aim to explore new ways of using azacitidine, either alone or in combination with other drugs, to improve outcomes for patients with conditions such as leukemia, myelodysplastic syndrome (MDS), and certain brain tumors. The research focuses on determining optimal dosing, administration methods, and potential benefits for patients who have not responded well to other treatments.

Table of Contents

What is Azacitidine?

Azacitidine is a medication used in the treatment of various blood disorders. It’s known by several names, including:

  • 5-Azacytidine
  • 5-AZC
  • Vidaza
  • Ladakamycin
  • Mylosar
This drug belongs to a class of medications called hypomethylating agents, which work by affecting how genes are expressed in cells[1].

What Conditions Does Azacitidine Treat?

Azacitidine is primarily used to treat several blood disorders, including:

  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[2].
  • Acute Myeloid Leukemia (AML): A type of blood cancer that starts in the bone marrow[3].
  • Chronic Myelomonocytic Leukemia (CMML): A rare blood cancer that affects certain white blood cells[1].
These conditions all involve problems with blood cell production or function, which Azacitidine aims to improve.

How Does Azacitidine Work?

Azacitidine works by influencing how genes are expressed in cells. Specifically, it:

  • Blocks certain enzymes that affect DNA, potentially stopping the growth of cancer cells[4].
  • Helps “turn on” genes that may have been incorrectly turned off in cancer cells.
  • May help restore normal blood cell production in the bone marrow.
By affecting gene expression, Azacitidine can potentially slow down or stop the growth of abnormal cells while allowing healthy cells to develop normally.

How is Azacitidine Administered?

Azacitidine can be given in several ways:

  • Subcutaneous (SC) injection: Injected under the skin[5].
  • Intravenous (IV) infusion: Given directly into a vein[6].
  • Oral tablets: Taken by mouth (a newer formulation being studied)[1].
The most common dosing schedule is 75 mg/m² (based on body surface area) given daily for 7 days, followed by 21 days of rest. This 28-day cycle is typically repeated for several months[2].

Potential Side Effects

Like all medications, Azacitidine can cause side effects. Common ones may include:

  • Fatigue
  • Nausea and vomiting
  • Diarrhea or constipation
  • Decreased blood cell counts, which can lead to increased risk of infections, bruising, or bleeding
  • Injection site reactions (if given subcutaneously)
It’s important to discuss potential side effects with your healthcare provider, as they can help manage these issues if they occur[7].

Current Clinical Trials

Azacitidine is being studied in various clinical trials to:

  • Improve its effectiveness when combined with other drugs[3].
  • Explore its use in different types of cancer[4].
  • Develop new formulations, such as oral tablets[1].
  • Compare it to other treatments or treatment combinations[6].
These trials aim to find better ways to use Azacitidine and potentially expand its use to help more patients.

Combination Therapies

Researchers are exploring how Azacitidine works when combined with other medications. Some combinations being studied include:

  • Azacitidine with Venetoclax for AML[3].
  • Azacitidine with Lenalidomide for high-risk MDS[2].
  • Azacitidine with Entinostat for lung cancer[4].
  • Azacitidine with Glasdegib for AML, MDS, and CMML[7].
These combinations aim to improve treatment outcomes by targeting cancer cells in multiple ways simultaneously.

Aspect Details
Drug Name Azacitidine (5-azacytidine, Vidaza)
Primary Conditions Studied Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndrome (MDS), Brain Tumors (Ependymoma)
Administration Methods Subcutaneous injection, Intravenous infusion, Direct infusion into brain ventricle (experimental)
Combination Therapies Sorafenib, PKC412 (Midostaurin), GM-CSF
Key Objectives Determine optimal dosing, Assess safety and efficacy, Explore new administration methods, Evaluate combination therapies
Notable Findings Potential for use in treatment-resistant cancers, Possible benefits in pre-transplant therapy, Experimental use in brain tumor treatment

FAQ

  • What is azacitidine and how does it work? Azacitidine is a drug designed to cause changes in certain genes that are thought to contribute to cancer growth. It works by blocking proteins that stop the function of tumor-fighting genes, potentially allowing these beneficial genes to work better in controlling cancer.
  • What types of cancer is azacitidine being studied for? Clinical trials are exploring the use of azacitidine for various types of cancer and blood disorders, including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), myelodysplastic syndrome (MDS), and certain types of brain tumors like recurrent posterior fossa ependymoma.
  • How is azacitidine administered in these clinical trials? The administration of azacitidine varies depending on the trial. It may be given by injection under the skin, through a vein, or in some experimental cases, directly into the brain's fourth ventricle. The frequency and duration of treatment also vary based on the specific study protocol.
  • Are there any side effects associated with azacitidine treatment? Like all medications, azacitidine can cause side effects. Common side effects may include nausea, vomiting, diarrhea, constipation, and fatigue. More serious side effects can occur, which is why patients are closely monitored during clinical trials.
  • Can azacitidine be combined with other treatments? Yes, many clinical trials are studying the combination of azacitidine with other drugs such as sorafenib, PKC412 (midostaurin), or GM-CSF. These combinations are being tested to see if they can improve the effectiveness of treatment for certain types of cancer.

Ongoing Clinical Trials on Azacitidine

  • A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

    Recruiting

    1 1 1 1
    Investigated drugs:
    France Spain

  • Study of Ziftomenib with drug combinations for adults with newly diagnosed acute myeloid leukemia with NPM1 or KMT2A genetic changes

    Recruiting

    1 1 1
    Investigated drugs:
    Belgium Czechia France Germany Greece Hungary +4

  • Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Czechia Denmark France Germany +6

  • Study on Azacitidine, Roginolisib, and Golcadomide for Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study Comparing Oral Azacitidine and Cedazuridine with Subcutaneous Azacitidine for Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Germany Hungary Italy Poland +1

  • Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Denmark Estonia Finland France +8

  • Study on the Effectiveness of Lisaftoclax and Azacitidine in Adults with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Finland France Germany +7

  • Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Denmark Estonia Finland France +8

  • Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Recruiting

    1 1 1 1
    Investigated drugs:
    Czechia Germany Italy Lithuania Portugal Romania +1

  • Study on Stopping Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia Who Are Responding to Treatment

    Recruiting

    1 1 1
    Investigated drugs:
    France

Glossary

  • Azacitidine: A drug designed to block certain genes in cancer cells, potentially allowing tumor-fighting genes to work better. It's also known as 5-azacytidine or Vidaza.
  • Myelodysplastic Syndrome (MDS): A group of disorders where the bone marrow does not produce enough healthy blood cells.
  • Acute Myeloid Leukemia (AML): A type of cancer that affects the blood and bone marrow, characterized by rapid growth of abnormal white blood cells.
  • Chronic Lymphocytic Leukemia (CLL): A type of cancer that affects white blood cells called lymphocytes, typically progressing more slowly than acute leukemias.
  • Ependymoma: A type of tumor that can form in the brain or spinal cord.
  • FLT3-ITD Mutation: A genetic mutation found in some leukemia patients that can affect treatment response and prognosis.
  • Allogeneic Stem Cell Transplantation: A procedure where a patient receives blood-forming stem cells from a genetically similar, but not identical, donor.
  • Cytoreduction: The reduction of the number of cancer cells, often through medication or other treatments before main therapy.
  • Ommaya Reservoir: A catheter system that allows drugs to be administered directly to parts of the brain.
  • Fourth Ventricle: One of the four connected fluid-filled cavities in the brain.

References

  1. https://clinicaltrials.gov/study/NCT01519011
  2. https://clinicaltrials.gov/study/NCT01053806
  3. https://clinicaltrials.gov/study/NCT06150040
  4. https://clinicaltrials.gov/study/NCT00387465
  5. https://clinicaltrials.gov/study/NCT01305135
  6. https://clinicaltrials.gov/study/NCT01812252
  7. https://clinicaltrials.gov/study/NCT04842604